Search for:
About Zealand
About Us
Disease Spotlights
History
Corporate Management
Corporate Governance
Corporate Social Responsibility
Board of Directors
Videos About Zealand
Transparency Reporting
R&D
Our Focus
Product Pipeline
Glepaglutide for SBS
Dasiglucagon for CHI
Survodutide (BI 456906) GLP-1/Glucagon Dual Agonist
Petrelintide-ZP8396 (Amylin Analog)
Dapiglutide (GLP-1/GLP-2 Dual Agonist)
Dasiglucagon for BHAP Systems
Partnering and In-licensing
What are Peptides?
Peptide Platform Video
Investor
Investor Relations
Corporate Presentation
Stock Information
Shareholder Portal
Financial Calendar
Financial Reports
Events
Annual General Meeting
SEC Filings
Analyst Coverage
Prospectus
Media
Zealand News
Media Inquiry
Downloads
Careers
Zealand as a Workplace
Meet Us
Positions
Personal Data in the Recruitment Process
Disclaimer: Beware of Recruitment Fraud
Contact
About Us
Disease Spotlights
Congenital Hyperinsulinism (CHI)
Short Bowel Syndrome (SBS)
History
Corporate Management
Corporate Governance
Audit Committee
Remuneration Committee
Nomination Committee
Scientific Committee
Corporate Social Responsibility
Board of Directors
Videos About Zealand
Transparency Reporting
Videos about Zealand
Zealand Pharma’s Peptide Platform
Zealand Pharma celebrates 20 years of achievements
Learn more about Short Bowel Syndrome (SBS)
Living with home parenteral nutrition
Henning A. Hansen’s story
Marianne Lauridsen’s story
Marianne Riis’s story